Researchers piloted optical genome mapping (OGM) alongside FISH analysis to improve diagnostic resolution in chronic lymphocytic leukemia (CLL). The study showed OGM can detect structural variants and complex rearrangements that standard FISH panels may miss, potentially refining risk stratification and therapeutic choices. Authors propose OGM as a complementary assay that captures genome‑wide structural variation without culture‑dependent karyotyping, which could shorten diagnostic workflows and reveal clinically actionable alterations. The work was presented as a pilot with implications for hematologic oncology labs evaluating cytogenomic pipelines. OGM’s utility will hinge on validation in larger cohorts, regulatory acceptance, and integration into existing diagnostic algorithms.